CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2016—Agena Bioscience and Horizon Discovery Group announced a supply and distribution agreement to launch iPlex reference standards for performance verification of oncology assays used on the MassArray System.
Under the partnership, Agena will offer multiplexed sets of iPlex-branded reference standards containing somatic variants in key oncogenic genes implicated in colon, lung, and skin cancers. These standards will be made from cell lines precisely engineered using Horizon’s proprietary genome engineering platform and will be provided at fixed and known allelic frequencies.
Agena also announced the commercial availability of its iPlex HS, a new chemistry that enables detection of genetic variants, including somatic mutations, translocations, and indels, that are present at levels as low as one percent in frequency. This capability is ideal for targeted genotyping of tumor biopsies in which higher sensitivity is critical and sample quantity is limited, such as with heterogeneous tumors and formalin-fixed tissue, as well as for orthogonal validation of next-generation sequencing results.
Agena Bioscience, 858-882-2800
Horizon Discovery Group, +44 (0) 1223 655 580